Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telescope Innovations Corp ( (TSE:TELI) ) has issued an update.
Telescope Innovations Corp reported a strong third fiscal quarter for 2025, with revenues of $1.4 million driven by the successful sales of its flagship product, DirectInject-LC™, which saw significant growth in Asia. The company is advancing its Self-Driving Lab platform in collaboration with Pfizer and has shipped its first battery-grade lithium sulfide samples to major industry groups, marking a strategic move in the battery supply chain. These developments, along with partnerships with Mettler Toledo, Pfizer, and Standard Lithium, are positioning Telescope for long-term success in the industry.
More about Telescope Innovations Corp
Telescope Innovations Corp is a chemical technology company focused on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries. The company specializes in creating flexible robotic platforms and artificial intelligence software to enhance experimental throughput, efficiency, and data quality, aiming to address significant challenges in health and sustainability.
Average Trading Volume: 72,231
Technical Sentiment Signal: Buy
Current Market Cap: C$23.36M
Find detailed analytics on TELI stock on TipRanks’ Stock Analysis page.